Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Orphanet Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
FLASH GENE
Symbol KRAS contributors: mct - updated : 21-08-2016
HGNC name v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
HGNC id 6407
ASSOCIATED DISORDERS
corresponding disease(s) NS3 , CFC5 , SMPS2
Other morbid association(s)
TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
tumoral somatic mutation      
in non small cell lung adenocarcinomas, in pancreatic cancer, in endometrial carcinoma (not in endometrial hyperplasia)and in thyroid cancer with poor prognosis
tumoral somatic mutation      
in MM and PPCL at an early stage, in rectal cancer and adenoma, and in colorectal tumors with poor prognosis
tumoral somatic mutation      
in high hyperdiploid childhood acute lymphoblastic leukemia
tumoral somatic mutation      
promotes colon cancer progression (mutation arise after loss of APC during colon cancer progression)
tumoral somatic mutation      
in colorectal cancer is correlated with increased proliferation and spontaneous apoptosis
tumoral somatic mutation     gain of function
activating mutations in the KRAS gene impair the ability of the KRAS protein to switch between active and inactive states, leading to cell transformation and increased resistance to chemotherapy and biological therapies targeting epidermal growth factor receptor
tumoral somatic mutation     gain of function
activating KRAS mutations is significantly correlated to an upregulation of 13 genes among them DUSP4, a MAP-kinase phosphatase, and SMYD3 in colorectal cancer
tumoral somatic mutation      
in autoimmune lymphoproliferative syndrome
constitutional     --low  
depletion of KRAS promotes proteasome degradation of BIRC5 (PMID
Susceptibility
Variant & Polymorphism
Candidate gene
Marker
Therapy target
SystemTypeDisorderPubmed
cancerdigestivecolon
importance of KRAS alterations as a potential therapeutic target for Colorectal cancer
osteoarticular  
RAS/ERK1/2 inhibition could be a potent strategy to treat RASopathies, including Noonan sdr
cancerdigestivepancreas
therapy target in pancreatic ductal adenocarcinoma (PDAC)
ANIMAL & CELL MODELS